The antiviral infusion was just revived as an early treatment for COVID patients. But the drug is relatively expensive and hard to administer, relegating it to what some are calling "stopgap" status.
The remedy is a new type of transcranial magnetic stimulation that's showing good results in just five days of treatment. For some patients, it's life-changing.
Slammed by COVID-19, many U.S. hospitals have put off essential procedures. Delays are leading to consequences like heart attacks and sending people to emergency rooms to get care.
NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it.
Microglia are amoeba-like cells that scour the brain for injuries and invaders. But sometimes the usually helpful cells go into overdrive and damage the brain, researchers say.
People who get infected with omicron are less likely to go to the hospital, go on a ventilator or die. But with the current huge volume of patients, hospitals are still struggling to treat them all.
So far the government has distributed about 300,000 doses of Evusheld, a new drug that protects against COVID-19. Some 7 million Americans could benefit from the drug right away.
Omicron may cause milder disease, but the sheer number of patients makes this wave far worse for the health care system. With packed emergency rooms, patients can wait days to get moved to a bed.
Paxlovid and molnupiravir have been authorized for emergency use to keep COVID-19 patients out of the hospital, but don't expect to be able to go to your usual pharmacy and get them.
The Moderna vaccine's ability to shield against infection drops sharply when tested on the omicron variant. But getting a booster pumps the protection back up again, new research suggests.
With a fast-growing winter surge upon us, self-testing kits remain expensive and hard to find. The reasons go back to the approach the U.S. took from the outset in developing tests.
A vaccine from a Canadian biotech firm Medicago has been found to be effective at preventing moderate to severe disease. It could soon become the first plant-based vaccine authorized for human use.
Omicron has many more mutations than previous variants of concern, a fact that raises questions about how effective existing vaccines will be against the new form of the coronavirus.
Pfizer researchers looking for a drug to treat SARS found clues that gave the company a head start in its quest for a pill to treat COVID-19, including the omicron variant.
